title: Is there a role for immune and anti-in-flammatory therapy in type 2 diabetes?
abstract: There is a growing body of evidence to suggest that type 2 diabetes is associated with a generalised activation of the innate immune system, in which there is a chronic low-grade inflammation. Further evidence for roles of inflammation in type 2 diabetes comes from clinical studies using either anti-inflammatory approaches or biological agents that target specific proinflammatory cytokine pathways to improve parameters of glucose control especially with IL-1β (Interleukin 1 β) antagonism and salsalate (non-acetylated prodrug of salicylate) treatment. In this review, recent evidence implicating the pathological involvement of the immune system in type 2 diabetes is examined, together with the role of potential treatment modalities targeting the immune system in the management of type 2 diabetes.
authors.affiliation: Unit of Endocrinology and Metabolism, Hull York Medical School, Hull, UK. thozhukat.sathyapalan@hyms.ac.uk
authors.forename: T
authors.initials: T
authors.lastname: Sathyapalan
authors.forename: S L
authors.initials: SL
authors.lastname: Atkin
mesh_terms: D054392:Adipokines / Q000097:blood; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D018925:Chemokines / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007167:Immunotherapy; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors
chemical_list: D054392:Adipokines; D000893:Anti-Inflammatory Agents; D018925:Chemokines; D017472:Receptors, Interleukin-1